Your AI-Trained Oncology Knowledge Connection!

News

Video

First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW

Author(s):

Heinz-Josef Lenz, MD

Dr. Heinz-Josef Lenz presents first results from the CheckMate 8HW trial, demonstrating that nivolumab plus ipilimumab significantly improves progression-free survival and overall response rates compared to nivolumab monotherapy in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer across all lines of therapy.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Yufei Liu, MD, PhD
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
the α-CORRECT study
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC
AGAVE-201
Kanwal P.S. Raghav, MBBS, MD
E. Gabriela Chiorean, MD, FASCO, clinical director, GI Medical Oncology Program, professor, Clinical Research Division, and affiliate investigator, Translational Science and Therapeutics Division Fred Hutchinson Cancer Center; professor, medicine, University of Washington; director, Clinical Research GI Oncology Program, University of Washington/Fred Hutch
Daniel B. Flora, MD, PharmD
Hideaki Bando, MD, PhD, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East,
Related Content
Andreas M. Kaiser, MD, professor, chief, Division of Colorectal Surgery, Department of Surgery, City of Hope
March 20th 2025

Comprehensive Communication Regarding CRC Surgery and Postoperative Complications Is Crucial

Marwan G. Fakih, MD
March 3rd 2025

FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD

The top 5 OncLive videos of the week cover insights in colorectal cancer, myeloma, HER2+ breast cancer, and KRAS G12X+ pancreatic ductal adenocarcinoma.
March 16th 2025

Five Under 5: Top Oncology Videos for the Week of 3/9

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

Colorectal Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 5th 2025

Nivolumab/Ipilimumab Combination Represents Potential Standard-of-Care Shift in MSI-H/dMMR mCRC

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.
March 1st 2025

The OncFive: Top Oncology Articles for the Week of 2/23